Edding Genor Group Holdings Limited (FRA:67N0)

Market Cap	331.41M
Revenue (ttm)	302.90M -2.3%
Net Income	48.62M +2.9%
EPS	0.03 +1.0%
Shares Out	n/a
PE Ratio	6.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1630
Previous Close	0.1530
Day's Range	0.1630 - 0.1630
52-Week Range	0.1520 - 0.5700
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About FRA:67N0

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for mult...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 1,545
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 67N0

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error